We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

109 hedge funds and large institutions have $144M invested in Aclaris Therapeutics in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 27 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 12

69% more call options, than puts

Call options by funds: $83K | Put options by funds: $49K

44% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 27

11% more funds holding

Funds holding: 98 → 109 (+11)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

34% less capital invested

Capital invested by funds: $217M → $144M (-$73.3M)

36.61% less ownership

Funds ownership: 122.51% → 85.9% (-37%)

Holders
109
Holders Change
+11
Holders Change %
+11.22%
% of All Funds
1.46%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
23
Increased
39
Reduced
27
Closed
12
Calls
$83K
Puts
$49K
Net Calls
+$34K
Net Calls Change
-$444K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$4.64M
2
DC
Decheng Capital
California
+$3.79M
3
BG
Bollard Group
Massachusetts
+$3.04M
4
Morgan Stanley
Morgan Stanley
New York
+$2.87M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.78M

Top Sellers

1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$6.99M
2
SB
Samsara BioCapital
California
-$5.91M
3
RSCM
Rock Springs Capital Management
Maryland
-$2.47M
4
PLC
Peapod Lane Capital
New York
-$1M
5
EAM
Exome Asset Management
New York
-$966K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
1
BML Capital Management
Indiana
$21.8M – – –
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$14.7M – – –
VC
3
Vivo Capital
California
$13.6M – – –
RSCM
4
Rock Springs Capital Management
Maryland
$7.72M -$2.47M -1,158,000 -19%
Vanguard Group
5
Vanguard Group
Pennsylvania
$7.6M +$1.38M +644,991 +15%
RCM
6
RA Capital Management
Massachusetts
$7.14M – – –
Millennium Management
7
Millennium Management
New York
$6.33M +$4.64M +2,175,101 +111%
DC
8
Decheng Capital
California
$6.18M +$3.79M +1,775,069 +78%
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$4.51M -$745K -349,113 -11%
Morgan Stanley
10
Morgan Stanley
New York
$3.7M +$2.87M +1,343,800 +125%
Marshall Wace
11
Marshall Wace
United Kingdom
$3.54M -$685K -321,139 -12%
LGM
12
Logos Global Management
California
$3.4M – – –
Acadian Asset Management
13
Acadian Asset Management
Massachusetts
$3.35M +$962K +451,044 +26%
SCM
14
Stonepine Capital Management
Oregon
$2.77M -$289K -135,563 -20%
BG
15
Bollard Group
Massachusetts
$2.18M +$3.04M +1,424,176 New
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$2.11M +$2.78M +1,302,694 +1,648%
BlackRock
17
BlackRock
New York
$2.08M +$220K +103,258 +8%
Qube Research & Technologies (QRT)
18
Qube Research & Technologies (QRT)
United Kingdom
$2.07M +$1.57M +735,737 +120%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$1.81M +$839K +393,140 +50%
Citadel Advisors
20
Citadel Advisors
Florida
$1.72M +$2.28M +1,066,734 +1,927%
AC
21
Aldebaran Capital
Indiana
$1.54M -$19.2K -9,000 -0.9%
Renaissance Technologies
22
Renaissance Technologies
New York
$1.46M +$215K +100,875 +12%
Deutsche Bank
23
Deutsche Bank
Germany
$1.41M – – –
MIM
24
Monashee Investment Management
Massachusetts
$1.36M – – –
Connor, Clark & Lunn Investment Management (CC&L)
25
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.32M -$93.4K -43,808 -5%
1
2 3 4 5

ACRS Hedge Fund Activity: Q1 2025 in Review

109 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2025, worth a combined $144M — down 34% from $217M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ACRS positions and 12 closed out — a net gain of 11 holders — while 39 added to existing stakes and 27 trimmed.

The largest buyer was Millennium Management, adding an estimated $4.64M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $6.99M sold.

  • 109 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2025, up from 98 in Q4 2024.
  • Funds reported $144M of Aclaris Therapeutics stock for Q1 2025, down 34% quarter-over-quarter.
  • 23 funds opened new Aclaris Therapeutics positions in Q1 2025 and 12 closed out, a net change of +11 holders.
  • The largest Aclaris Therapeutics buyer in Q1 2025 was Millennium Management, an estimated $4.64M added.
  • The largest Aclaris Therapeutics seller in Q1 2025 was Janus Henderson Group, an estimated $6.99M sold.

Based on aggregated 13F filings for Q1 2025.